Pfizer Acquires Baxter’s Vaccines for $635m

Pfizer yesterday announced that they have agreed to purchase two of Baxter International’s commercially marketed vaccines and part of Baxter’s production facilities for $635 million. The purchase will give Pfizer access to Baxter’s meningitis C jab NeisVac-C and FSME-IMMUN/TicoVac, a vaccine that helps protect against tick-borne encephalitis – an infection of the brain transmitted by

Continue Reading